Oncology, ISSN 0030-2414, 04/2007, Volume 71, Issue 1-2, pp. 32 - 39
Background: Prognosis of patients with metastatic soft tissue sarcomas (MSTS) is poor even after response to doxorubicin-based chemotherapy. We report phase II...
Clinical Study | Soft tissue sarcoma | High-dose chemotherapy | Metastasis | INTENSIVE CHEMOTHERAPY | COLONY-STIMULATING FACTOR | EUROPEAN ORGANIZATION | PHASE-II | ADULT | TRANSPLANTATION | THERAPY | ONCOLOGY | metastasis | CANCER-TREATMENT | BONE | soft tissue sarcoma | PLUS DOXORUBICIN | high-dose chemotherapy | Sarcoma - secondary | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Humans | Middle Aged | Salvage Therapy | Carboplatin - administration & dosage | Etoposide - administration & dosage | Male | Survival Rate | Transplantation, Autologous | Combined Modality Therapy | Granulocyte Colony-Stimulating Factor - therapeutic use | Sarcoma - therapy | Feasibility Studies | Ifosfamide - administration & dosage | Soft Tissue Neoplasms - pathology | Adult | Female | Peripheral Blood Stem Cell Transplantation | Soft Tissue Neoplasms - therapy | Comparative studies | Survival analysis | Oncology | Chemotherapy | Toxicology | Stem cells
Clinical Study | Soft tissue sarcoma | High-dose chemotherapy | Metastasis | INTENSIVE CHEMOTHERAPY | COLONY-STIMULATING FACTOR | EUROPEAN ORGANIZATION | PHASE-II | ADULT | TRANSPLANTATION | THERAPY | ONCOLOGY | metastasis | CANCER-TREATMENT | BONE | soft tissue sarcoma | PLUS DOXORUBICIN | high-dose chemotherapy | Sarcoma - secondary | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Humans | Middle Aged | Salvage Therapy | Carboplatin - administration & dosage | Etoposide - administration & dosage | Male | Survival Rate | Transplantation, Autologous | Combined Modality Therapy | Granulocyte Colony-Stimulating Factor - therapeutic use | Sarcoma - therapy | Feasibility Studies | Ifosfamide - administration & dosage | Soft Tissue Neoplasms - pathology | Adult | Female | Peripheral Blood Stem Cell Transplantation | Soft Tissue Neoplasms - therapy | Comparative studies | Survival analysis | Oncology | Chemotherapy | Toxicology | Stem cells
Journal Article
JAMA, ISSN 0098-7484, 03/2012, Volume 307, Issue 12, pp. 1265 - 1272
CONTEXT Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal...
MESYLATE | CRITERIA | MEDICINE, GENERAL & INTERNAL | KIT MUTATIONS | RESECTION | DOSE IMATINIB | RISK | RECURRENCE | PROGNOSTICATION | STRATIFICATION | Piperazines - administration & dosage | Gastrointestinal Neoplasms - genetics | Gastrointestinal Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Proto-Oncogene Proteins c-kit - genetics | Chemotherapy, Adjuvant | Gastrointestinal Stromal Tumors - genetics | Gastrointestinal Stromal Tumors - surgery | Drug Administration Schedule | Neoplasm Recurrence, Local - prevention & control | Pyrimidines - administration & dosage | Gastrointestinal Neoplasms - surgery | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Receptor, Platelet-Derived Growth Factor alpha - genetics | Pyrimidines - adverse effects | Survival Analysis | Aged | Benzamides | Clinical trials | Postoperative period | Drug therapy | Digestive system | Tumors | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
MESYLATE | CRITERIA | MEDICINE, GENERAL & INTERNAL | KIT MUTATIONS | RESECTION | DOSE IMATINIB | RISK | RECURRENCE | PROGNOSTICATION | STRATIFICATION | Piperazines - administration & dosage | Gastrointestinal Neoplasms - genetics | Gastrointestinal Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Proto-Oncogene Proteins c-kit - genetics | Chemotherapy, Adjuvant | Gastrointestinal Stromal Tumors - genetics | Gastrointestinal Stromal Tumors - surgery | Drug Administration Schedule | Neoplasm Recurrence, Local - prevention & control | Pyrimidines - administration & dosage | Gastrointestinal Neoplasms - surgery | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Receptor, Platelet-Derived Growth Factor alpha - genetics | Pyrimidines - adverse effects | Survival Analysis | Aged | Benzamides | Clinical trials | Postoperative period | Drug therapy | Digestive system | Tumors | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2005, Volume 128, Issue 1, pp. 66 - 72
Summary We studied 228 consecutive stem cell transplant recipients, screened for reactivation of human herpesvirus-6 (HHV-6) in peripheral blood and other...
human herpesvirus-6 | haematopoietic stem cell transplantation | bone marrow transplantation | graft versus host disease | human herpesvirus‐6 | Bone marrow transplantation | Graft versus host disease | Human herpesvirus-6 | Haematopoietic stem cell transplantation | VIRUS | HUMAN-HERPESVIRUS-6 INFECTION | BONE-MARROW-TRANSPLANTATION | GRAFT | RECIPIENTS | STRATEGIES | ENCEPHALITIS | HOST DISEASE | HEMATOLOGY | MANIFESTATIONS | Prospective Studies | Humans | Middle Aged | Risk Factors | Postoperative Period | Hematopoietic Stem Cell Transplantation | Roseolovirus Infections - diagnosis | DNA, Viral - analysis | Male | Herpesvirus 6, Human - physiology | Transplantation, Homologous | Graft vs Host Disease | Polymerase Chain Reaction - methods | Adolescent | Adult | Epstein-Barr Virus Infections - complications | Female | Transplantation Conditioning | Virus Activation
human herpesvirus-6 | haematopoietic stem cell transplantation | bone marrow transplantation | graft versus host disease | human herpesvirus‐6 | Bone marrow transplantation | Graft versus host disease | Human herpesvirus-6 | Haematopoietic stem cell transplantation | VIRUS | HUMAN-HERPESVIRUS-6 INFECTION | BONE-MARROW-TRANSPLANTATION | GRAFT | RECIPIENTS | STRATEGIES | ENCEPHALITIS | HOST DISEASE | HEMATOLOGY | MANIFESTATIONS | Prospective Studies | Humans | Middle Aged | Risk Factors | Postoperative Period | Hematopoietic Stem Cell Transplantation | Roseolovirus Infections - diagnosis | DNA, Viral - analysis | Male | Herpesvirus 6, Human - physiology | Transplantation, Homologous | Graft vs Host Disease | Polymerase Chain Reaction - methods | Adolescent | Adult | Epstein-Barr Virus Infections - complications | Female | Transplantation Conditioning | Virus Activation
Journal Article
Hematology/Oncology Clinics of North America, ISSN 0889-8588, 06/2005, Volume 19, Issue 3, pp. 565 - 571
Treatment of aggressive fibromatosis remains a clinical challenge. Although desmoids are a benign tumor entity, their locally aggressive behavior and tendency...
COMBINED SURGERY | MANAGEMENT | ONCOLOGY | POLYPOSIS | METHOTREXATE | COMBINATION CHEMOTHERAPY | VINBLASTINE | AGGRESSIVE FIBROMATOSIS | RADIOTHERAPY | HEMATOLOGY | RADIATION-THERAPY | CHILDREN | Fibromatosis, Aggressive - diagnosis | Pregnancy | Adenomatous Polyposis Coli - complications | Fibromatosis, Aggressive - therapy | Gardner Syndrome - etiology | Humans | Female | Fibromatosis, Aggressive - etiology | Adenomatous Polyposis Coli - pathology | Gardner Syndrome - therapy | Gardner Syndrome - diagnosis
COMBINED SURGERY | MANAGEMENT | ONCOLOGY | POLYPOSIS | METHOTREXATE | COMBINATION CHEMOTHERAPY | VINBLASTINE | AGGRESSIVE FIBROMATOSIS | RADIOTHERAPY | HEMATOLOGY | RADIATION-THERAPY | CHILDREN | Fibromatosis, Aggressive - diagnosis | Pregnancy | Adenomatous Polyposis Coli - complications | Fibromatosis, Aggressive - therapy | Gardner Syndrome - etiology | Humans | Female | Fibromatosis, Aggressive - etiology | Adenomatous Polyposis Coli - pathology | Gardner Syndrome - therapy | Gardner Syndrome - diagnosis
Journal Article
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, ISSN 1610-0379, 08/2013, Volume 11, Issue s6, pp. 1 - 116
This first German evidence-based guideline for cutaneous melanoma was developed under the auspices of the German Dermatological Society (DDG) and the...
HIGH-RISK MELANOMA | AMERICAN-JOINT-COMMITTEE | ISOLATED HEPATIC PERFUSION | POSITRON-EMISSION-TOMOGRAPHY | POLYMERASE-CHAIN-REACTION | SENTINEL LYMPH-NODE | RANDOMIZED PHASE-III | PRIMARY CUTANEOUS MELANOMA | QUALITY-OF-LIFE | ISOLATED LIMB PERFUSION | DERMATOLOGY | Practice guidelines (Medicine) | Melanoma
HIGH-RISK MELANOMA | AMERICAN-JOINT-COMMITTEE | ISOLATED HEPATIC PERFUSION | POSITRON-EMISSION-TOMOGRAPHY | POLYMERASE-CHAIN-REACTION | SENTINEL LYMPH-NODE | RANDOMIZED PHASE-III | PRIMARY CUTANEOUS MELANOMA | QUALITY-OF-LIFE | ISOLATED LIMB PERFUSION | DERMATOLOGY | Practice guidelines (Medicine) | Melanoma
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2005, Volume 23, Issue 24, pp. 5795 - 5804
Purpose The aim of this study was to identify factors predicting initial and late resistance of GI stromal tumor (GIST) patients to imatinib and to document...
CHRONIC MYELOGENOUS LEUKEMIA | SURVIVAL | AGENT | EORTC SOFT-TISSUE | GIST | EFFICACY | ONCOLOGY | SAFETY | STI-571 | MESYLATE THERAPY | Predictive Value of Tests | Prognosis | Humans | Middle Aged | Proportional Hazards Models | Drug Resistance, Neoplasm | Logistic Models | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Imatinib Mesylate | Disease Progression | Gastrointestinal Stromal Tumors - drug therapy | Pyrimidines - therapeutic use | Gastrointestinal Stromal Tumors - pathology | Adult | Female | Aged | Benzamides
CHRONIC MYELOGENOUS LEUKEMIA | SURVIVAL | AGENT | EORTC SOFT-TISSUE | GIST | EFFICACY | ONCOLOGY | SAFETY | STI-571 | MESYLATE THERAPY | Predictive Value of Tests | Prognosis | Humans | Middle Aged | Proportional Hazards Models | Drug Resistance, Neoplasm | Logistic Models | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Imatinib Mesylate | Disease Progression | Gastrointestinal Stromal Tumors - drug therapy | Pyrimidines - therapeutic use | Gastrointestinal Stromal Tumors - pathology | Adult | Female | Aged | Benzamides
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2008, Volume 14, Issue 23, pp. 7930 - 7934
Purpose: In patients with colorectal cancer (CRC), modulation of 5-fluorouracil (5-FU) by folinic acid (FA) improves response rate and overall survival...
folinic acid | reduces folates | colorectal cancer | HUMAN-COLON ADENOCARCINOMA | METHYLENETETRAHYDROFOLATE REDUCTASE | 5-FLUOROURACIL | LEUCOVORIN | ONCOLOGY | RANDOMIZED PHASE-III | FOLYLPOLYGLUTAMATE SYNTHETASE | FLUOROURACIL | CANCER | MODULATION | XENOGRAFTS | Leucovorin - administration & dosage | Leucovorin - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Humans | Antineoplastic Agents - therapeutic use | Tetrahydrofolates - analysis
folinic acid | reduces folates | colorectal cancer | HUMAN-COLON ADENOCARCINOMA | METHYLENETETRAHYDROFOLATE REDUCTASE | 5-FLUOROURACIL | LEUCOVORIN | ONCOLOGY | RANDOMIZED PHASE-III | FOLYLPOLYGLUTAMATE SYNTHETASE | FLUOROURACIL | CANCER | MODULATION | XENOGRAFTS | Leucovorin - administration & dosage | Leucovorin - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Humans | Antineoplastic Agents - therapeutic use | Tetrahydrofolates - analysis
Journal Article
BMC Musculoskeletal Disorders, ISSN 1471-2474, 2012, Volume 13, Issue 1, pp. 232 - 232
Background: Breast cancer is the most common malignancy and the second leading cause of death in women. Because bone metastases are a common finding in...
Breast cancer | Bone metastases | Surgical treatment of bone metastases | SURVIVAL | MANAGEMENT | SPINE | STATISTICS | DISEASE | RHEUMATOLOGY | ORTHOPEDICS | SURGICAL-TREATMENT | CARCINOMA | Breast Neoplasms - surgery | Bone Neoplasms - diagnosis | Humans | Middle Aged | Orthopedic Procedures - methods | Bone Neoplasms - secondary | Male | Treatment Outcome | Bone Neoplasms - surgery | Aged, 80 and over | Adult | Female | Aged | Breast Neoplasms - diagnosis | Care and treatment | Cancer patients | Prognosis | Orthopedic surgery | Medical records | Metastasis | Malignancy | Multivariate analysis | Bone surgery | Survival | imaging | Metastases | Bone cancer | Fractures | Orthopedics | Surgery | medical records | Age | Tumors
Breast cancer | Bone metastases | Surgical treatment of bone metastases | SURVIVAL | MANAGEMENT | SPINE | STATISTICS | DISEASE | RHEUMATOLOGY | ORTHOPEDICS | SURGICAL-TREATMENT | CARCINOMA | Breast Neoplasms - surgery | Bone Neoplasms - diagnosis | Humans | Middle Aged | Orthopedic Procedures - methods | Bone Neoplasms - secondary | Male | Treatment Outcome | Bone Neoplasms - surgery | Aged, 80 and over | Adult | Female | Aged | Breast Neoplasms - diagnosis | Care and treatment | Cancer patients | Prognosis | Orthopedic surgery | Medical records | Metastasis | Malignancy | Multivariate analysis | Bone surgery | Survival | imaging | Metastases | Bone cancer | Fractures | Orthopedics | Surgery | medical records | Age | Tumors
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2016, Volume 34, Issue 3, pp. 244 - 250
Purpose Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) with high-risk features, according to survival...
MESYLATE | PHASE-II TRIAL | THERAPY | ONCOLOGY | Gastrointestinal Stromal Tumors - surgery | Drug Administration Schedule | Administration, Oral | Gastrointestinal Neoplasms - drug therapy | Humans | Middle Aged | Gastrointestinal Neoplasms - surgery | Male | Antineoplastic Agents - administration & dosage | Disease-Free Survival | Gastrointestinal Stromal Tumors - drug therapy | Imatinib Mesylate - administration & dosage | Female | Aged | Chemotherapy, Adjuvant
MESYLATE | PHASE-II TRIAL | THERAPY | ONCOLOGY | Gastrointestinal Stromal Tumors - surgery | Drug Administration Schedule | Administration, Oral | Gastrointestinal Neoplasms - drug therapy | Humans | Middle Aged | Gastrointestinal Neoplasms - surgery | Male | Antineoplastic Agents - administration & dosage | Disease-Free Survival | Gastrointestinal Stromal Tumors - drug therapy | Imatinib Mesylate - administration & dosage | Female | Aged | Chemotherapy, Adjuvant
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2006, Volume 42, Issue 8, pp. 1093 - 1103
A recent randomized EORTC phase III trial, comparing two doses of imatinib in patients with advanced gastrointestinal stromal tumours (GISTs), reported dose...
PDGFRA | Genotype analysis | Targeted therapy | Gastrointestinal stromal tumours | Imatinib mesylate | KIT | SARCOMA-GROUP | targeted therapy | ACTIVATION | EFFICACY | TYROSINE KINASE | C-KIT | PHASE-II | imatinib mesylate | gastrointestinal stromal tumours | SIGNAL-TRANSDUCTION | genotype analysis | ONCOLOGY | BIOLOGY | INHIBITOR | PROGRESSION | Prognosis | Exons | Humans | Middle Aged | Genotype | Male | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Mutation - genetics | Imatinib Mesylate | Disease-Free Survival | Gastrointestinal Stromal Tumors - drug therapy | Pyrimidines - therapeutic use | Adult | Female | Proto-Oncogene Proteins c-kit - genetics | Aged | Retrospective Studies | Benzamides | Gastrointestinal Stromal Tumors - genetics | Tumors
PDGFRA | Genotype analysis | Targeted therapy | Gastrointestinal stromal tumours | Imatinib mesylate | KIT | SARCOMA-GROUP | targeted therapy | ACTIVATION | EFFICACY | TYROSINE KINASE | C-KIT | PHASE-II | imatinib mesylate | gastrointestinal stromal tumours | SIGNAL-TRANSDUCTION | genotype analysis | ONCOLOGY | BIOLOGY | INHIBITOR | PROGRESSION | Prognosis | Exons | Humans | Middle Aged | Genotype | Male | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Mutation - genetics | Imatinib Mesylate | Disease-Free Survival | Gastrointestinal Stromal Tumors - drug therapy | Pyrimidines - therapeutic use | Adult | Female | Proto-Oncogene Proteins c-kit - genetics | Aged | Retrospective Studies | Benzamides | Gastrointestinal Stromal Tumors - genetics | Tumors
Journal Article
BMC Palliative Care, ISSN 1472-684X, 04/2018, Volume 17, Issue 1, pp. 58 - 11
Background: Hospital costs and cost drivers in palliative care are poorly analysed. It remains unknown whether current German Diagnosis-Related Groups, mainly...
DRG | Palliative care | Costs and cost analysis | Reimbursement | Diagnosis related groups | Palliative care funding | REGRESSION | MORTALITY | SYSTEM | COST-EFFECTIVENESS | ADVANCED CANCER | ENGLISH | AUSTRALIAN CASEMIX CLASSIFICATION | SAVINGS | HEALTH CARE SCIENCES & SERVICES | CONSULTATION | HEALTH POLICY & SERVICES | OUTCOMES | Palliative treatment | Management | Regression analysis | Finance | Analysis | Medical care, Cost of
DRG | Palliative care | Costs and cost analysis | Reimbursement | Diagnosis related groups | Palliative care funding | REGRESSION | MORTALITY | SYSTEM | COST-EFFECTIVENESS | ADVANCED CANCER | ENGLISH | AUSTRALIAN CASEMIX CLASSIFICATION | SAVINGS | HEALTH CARE SCIENCES & SERVICES | CONSULTATION | HEALTH POLICY & SERVICES | OUTCOMES | Palliative treatment | Management | Regression analysis | Finance | Analysis | Medical care, Cost of
Journal Article
Cureus, ISSN 2168-8184, 03/2019, Volume 11, Issue 3, p. e4244
The aim of our study was to evaluate the outcome of alternative sequences of sunitinib followed by sorafenib versus sorafenib followed by sunitinib therapies...
Drugs | Studies | Medical prognosis | Kidney cancer | Metastasis | Patients | Cancer therapies
Drugs | Studies | Medical prognosis | Kidney cancer | Metastasis | Patients | Cancer therapies
Journal Article
13.
Full Text
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology, ISSN 0923-7534, 2014, Volume 25 Suppl 3, Issue suppl 3, pp. iii113 - 23
ADJUVANT CHEMOTHERAPY | PRIMITIVE NEUROECTODERMAL TUMOR | ONCOLOGY-GROUP | PROGNOSTIC-FACTORS | LOCAL RECURRENCE | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | NONMETASTATIC EWINGS-SARCOMA | DEDIFFERENTIATED CHONDROSARCOMA | PHASE-II | HIGH-DOSE IFOSFAMIDE | Bone Neoplasms - diagnosis | Prognosis | Bone Neoplasms - therapy | Follow-Up Studies | Humans | Health Planning Guidelines | Combined Modality Therapy | Sarcoma - diagnosis | Neoplasm Staging | Societies, Medical - standards | Sarcoma - therapy
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2005, Volume 41, Issue 12, pp. 1751 - 1757
In the EORTC-ISG-AGITG trial 946 patients with advanced gastro-intestinal stromal tumours (GIST) were randomised to receive 400 or 800 mg of imatinib daily. An...
Progression | Imatinib | GIST | Dose effects | TRIAL | MESYLATE | EFFICACY | ONCOLOGY | SAFETY | ANTICANCER AGENTS | imatinib | progression | PHASE-II | dose effects | Piperazines - administration & dosage | Pyrimidines - administration & dosage | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - administration & dosage | Imatinib Mesylate | Disease Progression | Feasibility Studies | Cross-Over Studies | Dose-Response Relationship, Drug | Gastrointestinal Stromal Tumors - drug therapy | Aged, 80 and over | Adult | Female | Aged | Benzamides
Progression | Imatinib | GIST | Dose effects | TRIAL | MESYLATE | EFFICACY | ONCOLOGY | SAFETY | ANTICANCER AGENTS | imatinib | progression | PHASE-II | dose effects | Piperazines - administration & dosage | Pyrimidines - administration & dosage | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - administration & dosage | Imatinib Mesylate | Disease Progression | Feasibility Studies | Cross-Over Studies | Dose-Response Relationship, Drug | Gastrointestinal Stromal Tumors - drug therapy | Aged, 80 and over | Adult | Female | Aged | Benzamides
Journal Article
JDDG - Journal of the German Society of Dermatology, ISSN 1610-0379, 2013, Volume 11, Issue 6, pp. 1 - 126
Journal Article
American Journal of Roentgenology, ISSN 0361-803X, 04/2005, Volume 184, Issue 4, pp. 1326 - 1331
We sought to evaluate the efficiency of (18)FDG PET, CT, and MRI for the preoperative staging of squamous cell carcinoma (SCC) of the head and neck region. MRI...
Diagnosis, Differential | Humans | Middle Aged | Male | Pharyngeal Neoplasms - diagnostic imaging | Tomography, X-Ray Computed | Carcinoma, Squamous Cell - diagnostic imaging | Lymphatic Metastasis | Carcinoma, Squamous Cell - diagnosis | Magnetic Resonance Imaging | Mouth Neoplasms - diagnosis | Pharyngeal Neoplasms - diagnosis | Sensitivity and Specificity | Aged, 80 and over | Adult | Female | Fluorodeoxyglucose F18 | ROC Curve | Aged | Tomography, Emission-Computed | Neoplasm Staging | Radiopharmaceuticals | Mouth Neoplasms - diagnostic imaging
Diagnosis, Differential | Humans | Middle Aged | Male | Pharyngeal Neoplasms - diagnostic imaging | Tomography, X-Ray Computed | Carcinoma, Squamous Cell - diagnostic imaging | Lymphatic Metastasis | Carcinoma, Squamous Cell - diagnosis | Magnetic Resonance Imaging | Mouth Neoplasms - diagnosis | Pharyngeal Neoplasms - diagnosis | Sensitivity and Specificity | Aged, 80 and over | Adult | Female | Fluorodeoxyglucose F18 | ROC Curve | Aged | Tomography, Emission-Computed | Neoplasm Staging | Radiopharmaceuticals | Mouth Neoplasms - diagnostic imaging
Journal Article
Clinical Nutrition, ISSN 0261-5614, 2015, Volume 34, Issue 6, pp. 1258 - 1265
Summary Purpose Evaluation of potential associations between plasma glutamine levels and the incidence of cancer related fatigue, physical performance, poor...
Gastroenterology and Hepatology | Inflammation | Solid tumors | Malnutrition | Cancer related fatigue | Glutamine | SURVIVAL | PERFORMANCE STATUS | CACHEXIA | MECHANISM | WEIGHT-LOSS | MUSCLE | SUPPLEMENTATION | PHASE | NUTRITION & DIETETICS | PLASMA | FREE AMINO-ACIDS | Glutamine - deficiency | Prognosis | Humans | Middle Aged | Fatigue - complications | Male | Motor Activity | Inflammation - blood | Malnutrition - complications | Nutrition Assessment | Inflammation - complications | Neoplasms - complications | Neoplasms - blood | Glutamine - blood | Adult | Female | Surveys and Questionnaires | Nutritional Status | Inflammation - diagnosis | Cross-Sectional Studies | Fatigue - blood | Biomarkers - blood | Electric Impedance | Aged | Malnutrition - blood | Fatigue | Care and treatment | Cancer patients
Gastroenterology and Hepatology | Inflammation | Solid tumors | Malnutrition | Cancer related fatigue | Glutamine | SURVIVAL | PERFORMANCE STATUS | CACHEXIA | MECHANISM | WEIGHT-LOSS | MUSCLE | SUPPLEMENTATION | PHASE | NUTRITION & DIETETICS | PLASMA | FREE AMINO-ACIDS | Glutamine - deficiency | Prognosis | Humans | Middle Aged | Fatigue - complications | Male | Motor Activity | Inflammation - blood | Malnutrition - complications | Nutrition Assessment | Inflammation - complications | Neoplasms - complications | Neoplasms - blood | Glutamine - blood | Adult | Female | Surveys and Questionnaires | Nutritional Status | Inflammation - diagnosis | Cross-Sectional Studies | Fatigue - blood | Biomarkers - blood | Electric Impedance | Aged | Malnutrition - blood | Fatigue | Care and treatment | Cancer patients
Journal Article